POCT

PremaLabs Diagnostics PL Mini (LS-4000) wins Pharmacy Innovation Product of the Year Award

Retrieved on: 
Monday, March 20, 2023
Pressure, Pharmacy, NEXT Woman of the Year awards, Diabetes, Anemia, Pharmacist, POCT, Patient, Health, GP, Men's Health, Nursing

LONDON, March 20, 2023 /PRNewswire/ -- PL Diagnostics Ltd (PremaLabs UK) today announced that its portable Point of Care Test (POCT) analyser, the PL Mini (LS-4000) has won the Pharmacy Innovation Product of the Year Award 2023, as voted for by the readers of Independent Community Pharmacist magazine.

Key Points: 
  • LONDON, March 20, 2023 /PRNewswire/ -- PL Diagnostics Ltd (PremaLabs UK) today announced that its portable Point of Care Test (POCT) analyser, the PL Mini (LS-4000) has won the Pharmacy Innovation Product of the Year Award 2023, as voted for by the readers of Independent Community Pharmacist magazine.
  • Neil Trainis, Editor of Independent Community Pharmacist said: "It was a well deserved win and congratulations to PremaLabs Diagnostics.
  • Our Pharmacy Product of the Year Awards were voted for by our readers and, for the first time, consumers, who made their feelings clear on the brands in community pharmacy that are most important to them."
  • Adam Martin, PremaLabs UK CEO said: "We are delighted to have won this year's Pharmacy Innovation Product of the Year Award and its endorsement by the pharmacists who have voted for us reinforces the interest we're seeing from community pharmacies at the moment.

Assure Tech Launches a New Platform - Comprehensive Health Solution

Retrieved on: 
Monday, March 6, 2023
Infection, Skin, Dog, Bacteria, Veterinarian, Microfluidics, POCT, Pet, Diagnosis, Pithing, POC, Cat, Virus, Medical imaging

World wide, strong demand for pet-related products and healthcare services has given rise to a US$100 billion industrial chain in pet economy.

Key Points: 
  • World wide, strong demand for pet-related products and healthcare services has given rise to a US$100 billion industrial chain in pet economy.
  • The pet healthcare services segment nowadays plays a crucial role in this sector due to the huge market demand and the high consumption expenditure.
  • To follow this trend, Assure Tech will soon launch a comprehensive pet health solution comprising of five technological platforms: colloidal gold, fluorescence immunoassay, POCT, microfluidics, and nucleic acid POC.
  • The fast testing systems by Assure Tech can reliably detect and diagnose common diseases in pets.

Assure Tech Launches a New Platform - Comprehensive Health Solution

Retrieved on: 
Monday, March 6, 2023
Infection, Skin, Dog, Bacteria, Veterinarian, Microfluidics, POCT, Pet, Diagnosis, Pithing, POC, Cat, Virus, Medical imaging

World wide, strong demand for pet-related products and healthcare services has given rise to a US$100 billion industrial chain in pet economy.

Key Points: 
  • World wide, strong demand for pet-related products and healthcare services has given rise to a US$100 billion industrial chain in pet economy.
  • The pet healthcare services segment nowadays plays a crucial role in this sector due to the huge market demand and the high consumption expenditure.
  • To follow this trend, Assure Tech will soon launch a comprehensive pet health solution comprising of five technological platforms: colloidal gold, fluorescence immunoassay, POCT, microfluidics, and nucleic acid POC.
  • The fast testing systems by Assure Tech can reliably detect and diagnose common diseases in pets.

Co-Diagnostics, Inc. Initiates Clinical Evaluations for its At-Home and Point-of-Care Co-Dx PCR Home™ Platform

Retrieved on: 
Wednesday, February 22, 2023
Infection, PCR, Patient, POCT, Point-of-care testing, Research, SALT, FDA, COVID-19, Pharmaceutical industry

The Company's real-time PCR platform has been developed for detection of infectious diseases in at-home and point-of-care settings, with anticipated multiplex panels to follow after receipt of the platform's initial regulatory authorization.

Key Points: 
  • The Company's real-time PCR platform has been developed for detection of infectious diseases in at-home and point-of-care settings, with anticipated multiplex panels to follow after receipt of the platform's initial regulatory authorization.
  • Because the evaluations are dependent on identifying and enrolling a particular number of both symptomatic and asymptomatic COVID-19-positive and -negative patients at testing sites, the Company will not be providing projected timelines for completion at this time.
  • "The commencement of our clinical evaluations represents the achievement of a profound milestone for our Company," remarked Dwight Egan, CEO of Co-Diagnostics.
  • We are excited to begin these clinical evaluations and to leverage the power of our groundbreaking science in this new and revolutionary platform."

Continuous Glucose Monitoring Fosters Blood Glucose Meters Industry Growth - Grand View Research, Inc.

Retrieved on: 
Wednesday, February 8, 2023
Benchmarking, CGM, Himawari (satellites), Traction, Insulin, Pan American Health Organization, Dexcom, Diagnosis, Innovation, Blood, POCT, Hypoglycemia, Diabetes, Blood sugar level, Red Data Book of the Russian Federation, POC, CDC, Intelligence, USD, Continuous glucose monitor, Disease, SAN, R, Self-management, COVID-19, PAHO, Abbott, Medical device, Retail, Pharmaceutical industry

An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.

Key Points: 
  • An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.
  • Blood glucose monitoring devices have witnessed increased traction across developing and developed countries, mainly due to the need to stay on track with blood sugar goals.
  • The growth trajectory is primarily attributed to the trend for continuous glucose monitoring (CGM) technologies to track blood sugar levels.
  • Blood glucose meters manufacturers and suppliers are expected to cash in on the prevailing growth potentials to expand their penetration across yet-to-be-penetrated areas.

Continuous Glucose Monitoring Fosters Blood Glucose Meters Industry Growth - Grand View Research, Inc.

Retrieved on: 
Wednesday, February 8, 2023
Benchmarking, CGM, Himawari (satellites), Traction, Insulin, Pan American Health Organization, Dexcom, Diagnosis, Innovation, Blood, POCT, Hypoglycemia, Diabetes, Blood sugar level, Red Data Book of the Russian Federation, POC, CDC, Intelligence, USD, Continuous glucose monitor, Disease, SAN, R, Self-management, COVID-19, PAHO, Abbott, Medical device, Retail, Pharmaceutical industry

An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.

Key Points: 
  • An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.
  • Blood glucose monitoring devices have witnessed increased traction across developing and developed countries, mainly due to the need to stay on track with blood sugar goals.
  • The growth trajectory is primarily attributed to the trend for continuous glucose monitoring (CGM) technologies to track blood sugar levels.
  • Blood glucose meters manufacturers and suppliers are expected to cash in on the prevailing growth potentials to expand their penetration across yet-to-be-penetrated areas.

ALiA BioTech’s One-stop Diagnostic Platform Brings Multiplex Testing to the Medical Front Line

Retrieved on: 
Monday, January 16, 2023
Stem Cells, FDA, Health, General Health, Other Science, Medical Devices, Research, Infectious Diseases, Genetics, Science, Veterinary, Urine, Blood, Urinary tract infection, Serum, Research, Biotechnology, POCT, Alia, Cough, Streptococcus pneumoniae, COVID-19, Respiratory syncytial virus, Point-of-care testing, Vaccine, Medical device

Driven by the Covid-19 pandemic, the market for point-of-care testing (POCT) is seen to double in size compared to pre-pandemic levels.

Key Points: 
  • Driven by the Covid-19 pandemic, the market for point-of-care testing (POCT) is seen to double in size compared to pre-pandemic levels.
  • ALiA BioTech group took on this challenge 10 years ago and is now ready to deploy a next-generation rapid diagnostic platform that can conduct multiplex testing in a single biochip within 15 minutes.
  • Having completed research and development of its proprietary microfluidic and microarray technologies, ALiA is ready to scale up the manufacturing of multiplex products for different disease panels.
  • ALiA analyser and its biochip panels for respiratory infection and tropical fever have obtained Europe’s CE marks, with the accredited ISO 13485 medical device quality management system.

Meihua International Medical Technologies Co., Ltd. Enters into Strategic Partnership with Getein Biotech Inc. to Jointly Produce and Sell Covid-19 Antigen Test Kits and IVDs

Retrieved on: 
Wednesday, January 11, 2023
GMP, Research, III, Certification, Pandemic, India–Singapore Comprehensive Economic Cooperation Agreement, Workforce, Global health, POCT, US, National Medical Products Administration, IVD, II, COVID-19, Marketing, Medical device, Animal, Vaccine

The production base is equipped with 52 new fully automated Covid-19 antigen test kit production lines.

Key Points: 
  • The production base is equipped with 52 new fully automated Covid-19 antigen test kit production lines.
  • Jiangsu Huadong will hire an additional workforce of more than 400 workers and 35 technology staff who will safeguard production of all products.
  • As a result, sales of antigen test kits in China have increased by more than 300% during the first week of December 2022, according to media reports.
  • Covid antigen test products have been added to China's resident welfare procurement protection program, so future sales of the product are expected to remain robust.

Shineco, Inc. Subsidiary Receives Prior Approval Supplement from the NMPA Jiangsu Bureau for the Marketing Approval of “Cardiac 5-Minute Test”

Retrieved on: 
Monday, December 19, 2022
Death, Myocardial infarction, Heart, Myoglobin, AMI, POCT, SISI, Guideline, CBP, Cardiovascular disease, Prognosis, Point-of-care testing, Diagnosis, Marketing, International, Medical device, Chinese

We believe it is a breakthrough of the clinical diagnosis of AMI and takes only 5 minutes to complete detection.

Key Points: 
  • We believe it is a breakthrough of the clinical diagnosis of AMI and takes only 5 minutes to complete detection.
  • Cardiovascular disease is the leading cause of death in the world, especially for those over 50 years old.
  • However, current lab tests cannot meet this demand and need over 20 minutes upon arrival to obtain the test result.
  • “We are very glad to receive the first review report from the Chinese FDA Bureau for our application of the marketing approval of the Cardiac 5-minute Test.

Global Cardiac Troponin (Troponin I and Troponin T) Diagnostics Market Forecasts and Opportunities to 2025 with Abbot, Roche, and Siemens Healthineers Dominating as New Players Enter the Market - ResearchAndMarkets.com

Retrieved on: 
Friday, December 23, 2022
Medical Devices, Health, Troponin, Myocardial infarction, Troponin I, Research, Biomarker, Laboratory, MI, Siemens Healthineers, Hospital, POCT, Patient, EDS, Physician, Point-of-care testing, Diagnosis, Medical device, CTN

The "Cardiac Troponin Diagnostics - Forecasts and Opportunities to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Troponin Diagnostics - Forecasts and Opportunities to 2025" report has been added to ResearchAndMarkets.com's offering.
  • Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics.
  • In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.
  • The analyst's research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating.